# Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)

> **NCT06926790** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 69 (estimated)

## Conditions studied

- Lung Cancer - Non Small Cell

## Interventions

- **DRUG:** Nivolumab & Ipilimumab

## Key facts

- **NCT ID:** NCT06926790
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2030-03-31
- **Final completion:** 2030-10-31
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926790, "Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06926790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*